Batten disease, also known as neuronal ceroid lipofuscinosis, refers to a family of inherited disorders in which waste materials accumulate inside lysosomes, the recycling compartments of the cell. The resulting buildup, particularly in neurons, leads to progressive vision loss, seizures, motor decline, and early death. More than a dozen genes have been linked to different forms of the disease, yet for many of the encoded proteins, including CLN8, the normal function has remained frustratingly vague. CLN8 was known to sit in the endoplasmic reticulum and to travel along an ER-to-Golgi recycling pathway, but what it actually did during those journeys was unclear.

The new work answers that question with striking specificity. Two independent lines of investigation converged on the same conclusion: CLN8 catalyzes the acyl-CoA-dependent acylation of glycerophosphoglycerol, a small phosphorylated glycerol backbone, to produce lysophosphatidylglycerol. That reaction is the committed first step in a pathway that ultimately generates bis(monoacylglycero)phosphate, or BMP, a lipid so structurally peculiar that it is found almost exclusively in late endosomes and lysosomes, where it makes up a substantial fraction of the internal membrane surfaces.

The stereochemical detail matters. BMP is one of the very few lipids in mammalian cells with an unusual sn-1:sn-1′ glycerophosphate configuration, the mirror image of the configuration found in nearly every other glycerophospholipid. Because standard phospholipases cannot easily degrade this reversed architecture, BMP is intrinsically resistant to breakdown, an ideal property for a lipid that must persist in the harsh, enzyme-dense interior of the lysosome. Demonstrating that CLN8 is a stereospecific acyltransferase means the protein does not merely participate vaguely in lipid traffic; it selects the correct substrate, transfers the correct fatty acid chain from acyl-CoA, and initiates the construction of this biologically distinctive molecule.

Why should the failure to make BMP cause a brain disease? The answer lies in the lysosome’s operating principles. Lysosomes degrade cellular debris, damaged organelles, and macromolecules through the action of acid hydrolases, and many of those hydrolases require a membrane environment that can accept and present lipidated cargo. BMP is indispensable for the formation of intraluminal vesicles within multivesicular bodies, the structures in which lipid and protein cargo are delivered to degradative enzymes. Without adequate BMP, the sorting and degradation of cargo falters, and undigested material begins to pile up, precisely the hallmark pathology of Batten disease.

The experimental logic behind the discovery illustrates the power of modern lipid biochemistry combined with genetics. Rather than inferring function from protein interactions or localization alone, the researchers directly tested whether CLN8-containing preparations could convert glycerophosphoglycerol into lysophosphatidylglycerol in an acyl-CoA-dependent manner. The activity tracked with CLN8, was lost when CLN8 was removed or inactivated, and was restored when functional CLN8 was reintroduced. Disease-associated mutations in the protein compromised the enzymatic output, tying the biochemistry directly to the clinical syndrome. Complementary studies reached the same enzymatic assignment from different starting points, giving the conclusion unusual robustness.

Placing CLN8 in the pathway also resolves a long-standing gap. Scientists had identified downstream enzymatic steps that convert lysophosphatidylglycerol into BMP, and they knew where BMP accumulated, but the enzyme that supplies the pathway’s first committed product had been elusive. Identifying CLN8 as the acyltransferase means the biosynthetic route from a simple glycerophosphate precursor to the lysosome’s signature lipid is now, in outline, complete. It also explains previous observations that cells lacking CLN8 show abnormalities in lysosomal lipid composition and in the morphology of late endocytic compartments.

There are broader implications for membrane biology as well. CLN8 belongs to a family of ER-associated proteins, several of which have been linked to lysosomal storage diseases, that shuttle between the endoplasmic reticulum and the Golgi apparatus. If CLN8 performs its acyltransferase function at the ER or in transit, lipid synthesis may be spatially coupled to the trafficking routes that supply the endolysosomal system. That would suggest a model in which the cell builds a degradative lipid at its manufacturing hub and ships it forward, with CLN8 acting both as enzyme and possibly as escort. Testing that model will be a central task for future work.

For patients and families, the discovery does not translate immediately into therapy, but it changes the landscape of what therapy could look like. If the primary defect in CLN8 disease is a shortfall of BMP, then interventions that restore BMP levels, supply downstream lipid intermediates, or enhance parallel pathways for lysosomal membrane remodeling become plausible strategies. Enzyme replacement is complicated by the fact that CLN8 is an integral membrane protein embedded in intracellular membranes, a notoriously difficult class of therapeutic target. Small molecules that boost residual CLN8 activity, chaperone misfolded variants, or bypass the blocked step chemically are the kinds of approaches the new mechanistic understanding now makes testable.

The study also adds momentum to a growing realization that many so-called storage diseases are, at their core, diseases of lipid metabolism. As genome-encoded enzymes of lipid synthesis and remodeling continue to be matched with the disorders that arise when they fail, the field moves closer to a unified map connecting genes, membranes, and cellular decline. For CLN8, the journey from a disease gene of unknown purpose to a defined stereospecific acyltransferase is a striking example of that progress, and a reminder that even the most opaque proteins eventually surrender their function to patient biochemical scrutiny.

Subject of Research: Enzymatic function of the Batten disease protein CLN8 in bis(monoacylglycero)phosphate lipid biosynthesis

Article Title: The Batten disease protein CLN8 is a stereospecific acyltransferase in bis(monoacylglycero)phosphate biosynthesis

Article References: Sheokand, P. K., Lacabanne, D., James, A. M., Della Vecchia, S., Ruprecht, J. J., van der Kleij, J., Turner, K., Müller-Niva, J., Salo, M. H., Jenkins, B., Leese, S. K., Juneja, N., Yu, C. S., Booth, C. D., King, M. S., Uusimaa, J., Weimer, J. M., Koulman, A., Hinttala, R., … Petkevicius, K. (2026). The Batten disease protein CLN8 is a stereospecific acyltransferase in bis(monoacylglycero)phosphate biosynthesis. Nature Cell Biology. https://doi.org/10.1038/s41556-026-02061-0

Image Credits: AI Generated

DOI: 10.1038/s41556-026-02061-0

Keywords: Batten disease, CLN8, lysosomal storage disorders, bis(monoacylglycero)phosphate, lipid biosynthesis, acyltransferase, endoplasmic reticulum, lysosome, neuronal ceroid lipofuscinosis, lipid metabolism, glycerophosphoglycerol, neurodegeneration

Batten disease, the most common form of neuronal ceroid lipofuscinosis, is a group of inherited lysosomal storage disorders in which waste materials build up inside cells, particularly the neurons of the brain and retina. Children affected by CLN8 mutations can experience seizures, progressive vision loss, motor deterioration and cognitive decline, and most forms of the disease remain fatal. Roughly a dozen genes have been linked to the various forms of Batten disease, and while many of the implicated proteins have been localized to lysosomes or the endoplasmic reticulum, the precise biochemical functions of several of them have remained stubbornly elusive. CLN8, a small transmembrane protein resident in the endoplasmic reticulum, has been one of the most enigmatic.

The new work began with a deceptively simple question: how do cells manufacture bis(monoacylglycero)phosphate, a lipid so distinctive that some researchers have described it as the fingerprint of the late endosome? Unlike the canonical phospholipids that form bilayer membranes throughout the cell, BMP has an unusual stereochemical configuration and a peculiar sn-1, sn-1′ glycerophosphate backbone. It is found almost nowhere else in the cell except the internal vesicles of late endosomes and lysosomes, where it plays a central role in lipid sorting and degradation. Despite its importance, the enzymatic machinery responsible for synthesizing BMP had never been definitively identified, leaving a conspicuous gap in cell biology.

Textbook descriptions of phospholipid synthesis rely on a well-characterized set of enzymes in the endoplasmic reticulum that build phosphatidic acid and its derivatives using glycerol-3-phosphate as a scaffold. That canonical pathway, however, does not explain how BMP is made. Previous biochemical studies had suggested the existence of an alternative, non-canonical route that starts from glycerophosphoglycerol rather than glycerol-3-phosphate, but the enzyme that would initiate this pathway by converting glycerophosphoglycerol into lysophosphatidylglycerol had remained unidentified. The two studies now converge on the answer: CLN8 itself performs this acyltransferase reaction, using acyl-CoA molecules as fatty acid donors to acylate glycerophosphoglycerol.

In technical terms, the researchers showed that CLN8 catalyzes the acyl-CoA-dependent acylation of glycerophosphoglycerol, producing lysophosphatidylglycerol. This lysophospholipid is then converted, by subsequent enzymatic steps, into bis(monoacylglycero)phosphate. The discovery assigns a genuine enzymatic function to a protein that had previously been suspected of acting as a transporter or chaperone, and it places CLN8 at the very entry point of a biosynthetic route that supplies the late endocytic pathway with one of its signature lipids. The reactions were traced to the endoplasmic reticulum, consistent with CLN8’s known subcellular localization, implying that BMP precursors must be trafficked from their site of synthesis to the acidic compartments where the mature lipid accumulates.

The significance of this pathway assignment extends well beyond the technical satisfaction of filling in a missing enzymatic step. Bis(monoacylglycero)phosphate is indispensable for the normal functioning of lysosomes. It serves as a platform for the binding and activation of acid sphingomyelinase and other lipid-degrading enzymes, participates in the sorting of cholesterol and other lipids within the endolysosomal system, and is required for the proper vesicular trafficking that allows lysosomes to digest cellular debris. When BMP levels fall, these processes falter, and the consequences in neurons, which are extraordinarily dependent on continuous membrane turnover, can be severe. A failure to produce this lipid could therefore plausibly explain much of the cellular pathology observed in CLN8 Batten disease.

That connection is precisely what makes the new findings so consequential for the Batten disease field. Mutations in the CLN8 gene, which range from missense changes that impair protein function to larger deletions, give rise to two overlapping clinical presentations: a progressive epilepsy-ataxia syndrome and a more generalized classic Batten phenotype. By establishing that CLN8 is the acyltransferase that initiates BMP synthesis, the studies transform CLN8 from a protein of unknown function into an enzyme whose substrate, cofactor and product are now defined. This opens the door to measuring BMP and related lipids as biomarkers in patients, and to screening for small molecules that might restore pathway flux in cells carrying CLN8 mutations.

The identification of a non-canonical phospholipid pathway also resonates with a broader trend in cell biology. Over the past decade, researchers have come to appreciate that the canonical Kennedy pathway and its relatives do not account for every lipid a cell needs, and that alternative routes operate in specific organelles and under specific physiological conditions. Lysophosphatidylglycerol, the product of the CLN8-catalyzed reaction, has previously been detected in cells but its biosynthetic origin was unclear. Assigning its production to CLN8 resolves that ambiguity and suggests that related acyltransferase activities may await discovery in other corners of the endomembrane system. It also raises the possibility that other unsolved lysosomal storage disorders may stem from defects in equally obscure lipid biochemistry.

For the immediate future, the studies are expected to redirect experimental attention toward the steps downstream of CLN8. If lysophosphatidylglycerol is the direct precursor of BMP, then the enzymes that convert the former into the latter, and the transport mechanisms that move these lipids between the endoplasmic reticulum and the late endosome, become obvious targets for investigation. Understanding how the pathway is regulated, how it responds to cellular stress, and how mutations that partially impair CLN8 function translate into reduced BMP production will all be critical next steps. The fact that two independent studies arrived at the same conclusion through different approaches lends particular confidence to the central claim and suggests the finding will withstand the scrutiny that follows any major discovery.

Batten disease remains without a cure, and therapies developed to date, including enzyme replacement and gene therapy approaches for other subtypes, have delivered only partial benefits. Discoveries like this one, which replace biochemical mystery with molecular mechanism, are the raw material from which such therapies are ultimately built. By revealing that the ER-associated protein CLN8 enables a non-canonical phospholipid synthesis pathway, the researchers have not only solved a long-standing puzzle in lipid biochemistry but have also handed clinicians and drug developers a concrete, measurable process that can now be interrogated in patients and models alike. For families affected by CLN8 disease, the work represents a meaningful step from description toward explanation, and from explanation, eventually, toward intervention.

Subject of Research: The enzymatic role of the Batten disease protein CLN8 in a non-canonical phospholipid synthesis pathway

Article Title: Batten disease protein CLN8 enables a non-canonical phospholipid synthesis pathway

Article References: Breithofer, J., Fawzy, N., Zitta, C., Tischitz, M., Bulfon, D., Hofmann, C., Hartig, L., Wagner, C., Grabner, G. F., Pirchheim, A., Lass, A., Taschler, U., Turner, K., Petkevicius, K., Stelzl, U., Kratky, D., Breinbauer, R., & Zimmermann, R. (2026). Batten disease protein CLN8 enables a non-canonical phospholipid synthesis pathway. Nature Cell Biology. https://doi.org/10.1038/s41556-026-02059-8

Image Credits: AI Generated

DOI: 10.1038/s41556-026-02059-8

Keywords: Batten disease, CLN8, phospholipid synthesis, lysophosphatidylglycerol, bis(monoacylglycero)phosphate, lysosome, endoplasmic reticulum, lipid biochemistry, neuronal ceroid lipofuscinosis, neurodegeneration, acyltransferase, endolysosomal pathway

CLN3 Batten disease, formally known as juvenile neuronal ceroid lipofuscinosis, is the most common form of a family of inherited lysosomal storage disorders and affects roughly one in 100,000 live births worldwide. It is caused by mutations in the CLN3 gene, with approximately 85 percent of patients carrying the same genetic defect: a deletion of about one kilobase of DNA that removes exons 7 and 8. Children with the disease typically develop normally until between the ages of four and twelve, when vision loss begins. That vision loss progresses to blindness, followed by cognitive decline, motor deterioration, seizures and brain atrophy, culminating in premature death between the ages of 15 and 30. At the cellular level, the disease is marked by the buildup of autofluorescent storage material inside cells, whose major protein component is subunit C of the mitochondrial ATP synthase enzyme, a molecular fingerprint of failing cellular housekeeping.

The CLN3 protein itself is a transmembrane protein that resides primarily in endosomes and lysosomes, the cell’s recycling and degradation compartments, and although it has been linked to cellular homeostasis and neuronal survival, its precise function has remained elusive. For decades, research into the disease has been dominated by a neuron-centric view, focused on the nerve cells that die as the disease progresses. But an accumulating body of evidence has challenged that framing. Studies in mouse models have shown that glial activation precedes the loss of neurons, and that the locations where glial cells become activated accurately predict where neurons will subsequently die. Even more strikingly, laboratory co-culture experiments have demonstrated that glial cells lacking functional CLN3 are toxic to both healthy and mutant neurons, while adding healthy glial cells to mutant neurons largely rescues their survival. In other words, the supportive cells of the brain may be active participants in the neurodegeneration rather than innocent bystanders.

To interrogate the role of astrocytes specifically, the team took skin biopsy fibroblasts from a Norwegian CLN3 patient homozygous for the canonical 1 kb deletion and reprogrammed them into induced pluripotent stem cells using a Sendai virus-based reprogramming kit. Those pluripotent cells were then guided through a carefully choreographed differentiation pipeline: first into neural stem cells using small molecule inhibitors including CHIR99021 and SB431542, then into glial progenitor cells nourished with FGF-2 and EGF, and finally into mature astrocytes driven by leukemia inhibitory factor, EGF and ciliary neurotrophic factor over a maturation period of four weeks. The resulting cells expressed a suite of astrocyte markers — GFAP, S100β, ALDH1L1 and the glutamate transporter EAAT1/GLAST — at levels confirming successful and pure differentiation, while neuronal and oligodendrocyte markers remained minimal. Quantitative PCR confirmed the patient cells carried two mutated CLN3 alleles, and targeted mass spectrometry revealed that the truncated mutant CLN3 protein was not detectable at all in patient-derived cells, confirming that the deletion effectively abolishes CLN3 protein production.

With a validated cellular model in hand, the researchers performed an integrated analysis of both the transcriptome, using whole-transcriptome RNA sequencing, and the proteome, using label-free quantitative mass spectrometry on a timsTOF Pro 2 instrument in PASEF mode. The scale of the effort was considerable: multiple clones from two healthy control individuals and from the patient, each differentiated in triplicate, generated thousands of differentially expressed genes and proteins that could be compared across the developmental trajectory from stem cell to astrocyte. Gene set enrichment analysis of these datasets revealed the study’s central surprise. While conventional wisdom held that CLN3 loss should primarily disrupt lysosomal function, the young astrocytes showed only subtle lysosomal alterations. The lysosomal marker LAMP1 was present at similar levels in patient and control cells, and processes related to lysosomal protein catabolism were enriched to a similar degree in both genotypes during differentiation.

The mitochondrial story was entirely different, and it unfolded in two distinct phases. In the patient’s induced pluripotent stem cells, gene expression data showed underrepresentation of the mitochondrial respiratory chain complex I, accompanied by signatures of negative regulation of TORC1, a master growth and metabolism regulator — a combination previously observed in yeast models lacking the CLN3 homologue. But when the cells matured into astrocytes, the pattern inverted dramatically: proteins belonging to respiratory chain complexes I and IV, including NADH dehydrogenase components and the mitochondrial respirasome, were significantly overrepresented in the patient-derived cells. This contrasts sharply with the downregulation of these same complexes typically observed in CLN3-deficient neurons. Mitochondrial DNA copy number measurements confirmed that the patient astrocytes did not simply contain more mitochondria; instead, they appeared to pack more respiratory supercomplex proteins into their inner mitochondrial membranes, which themselves showed signs of disorganized structure, with genes governing mitochondrial fusion and inner membrane organization downregulated.

This mitochondrial upheaval rippled into lipid metabolism. The team found elevated levels of ELOVL1, the enzyme responsible for elongating very-long-chain saturated fatty acids, suggesting a shift toward production of longer saturated lipid species — a potentially dangerous change, given that elevated ELOVL1 activity has been linked to neurotoxicity in reactive astrocytes through saturated lipid production. At the same time, ELOVL5 levels dropped slightly, implying reduced synthesis of polyunsaturated fatty acids that maintain membrane fluidity. Fatty acid synthesis enzymes such as ACACA and FASN were downregulated, while the β-oxidation enzymes ACOX1 and ACADVL were upregulated, pointing to a metabolic pivot away from lipid construction and toward fatty acid burning. Notably, ACADS, which handles short-chain fatty acid oxidation and is normally upregulated during healthy astrocyte differentiation, failed to rise in the patient cells, suggesting the metabolic adaptation itself was broken. Because astrocytes account for the oxidation of free fatty acids that represents roughly 20 percent of the brain’s total energy expenditure, these defects strike at the heart of cerebral energy economics.

The dysregulated fat metabolism and aberrant respiratory chain activity came with a third signature: an intensified oxidative stress response. Levels of glutathione synthetase, which produces the cell’s principal antioxidant, were substantially increased in patient cells, as were the glutathione-conjugating enzymes GSTK1 and GSTZ1, along with catalase, NQO1 and the mitochondrial superoxide dismutase SOD2. The researchers interpret this as a compensatory counterattack against elevated reactive oxygen species generated by runaway peroxisomal β-oxidation — ACOX1 activity produces hydrogen peroxide as a byproduct — combined with impaired detoxification of partially oxidized fatty acid intermediates. Prior studies have documented increased oxidative stress in CLN3 lymphoblasts and fibroblasts, and work in fruit flies has shown that CLN3 loss increases vulnerability to oxidative damage while CLN3 overexpression confers resistance, lending independent support to the connection the Norwegian team has now drawn in human astrocytes.

Beyond metabolism, the analysis surfaced evidence of deeper epigenetic rewiring. A multifactorial statistical analysis disentangling the effects of genotype and cell type identified 363 genes whose expression patterns diverge specifically in the patient during astrocyte differentiation, with significant overrepresentation of genes involved in histone H3 and H4 lysine methylation. In patient cells, chromatin-related terms associated with open, transcriptionally active states — such as binding of acetylated histones — were underrepresented, while repressive machinery, including polycomb group complexes and heterochromatin-associated terms, was upregulated. The authors suggest this reflects a global shift toward a more compacted, transcriptionally restrictive chromatin landscape, potentially locking developing astrocytes into aberrant functional states. Additional dysregulation was seen in extracellular matrix genes involved in remodeling, synaptic support and neuroinflammatory signaling, hinting that mutant astrocytes undergo a reactive transformation that could compromise their support of neurons even before overt cell death begins.

The study is not without limitations, which the authors acknowledge candidly. All patient-derived material came from a single individual, so some observed phenotypes could reflect that patient’s unique genetic background rather than CLN3 loss alone, and extending the work to additional patient lines or gene-corrected isogenic controls would strengthen the conclusions. Nevertheless, the findings carry significant therapeutic implications. If mitochondrial dysfunction in astrocytes indeed precedes the lysosomal breakdown that defines advanced disease, then interventions aimed at restoring mitochondrial health — improving respiration, normalizing lipid metabolism, or bolstering antioxidant capacity — could preserve astrocyte function, and through it neuronal survival, potentially delaying disease progression. The team proposes that future work in more complex human models, such as brain organoids incorporating multiple cell types, should be used to establish the precise temporal relationship between astrocytic mitochondrial failure and neuronal death. Because mitochondrial dysfunction is a common thread linking Alzheimer’s, Parkinson’s, Huntington’s and ALS, insights from this rare pediatric disease may ultimately illuminate mechanisms of far more common neurodegenerative conditions, including those associated with aging, underscoring once again that understanding rare diseases can pay dividends well beyond the patient communities they directly affect.